CNCE


Monday’s Biotech Insights: Concert Pharmaceuticals Inc (CNCE), TG Therapeutics Inc (TGTX)

Concert Pharmaceuticals Inc (NASDAQ:CNCE) shares skyrocketed today following the news that Vertex Pharmaceuticals (NASDAQ:VRTX) will acquire Concert’s deuterated Kalydeco variant, CTP-656, for $160 million upfront with …

Biotech Stock Updates and More

NASDAQ: CHRS– We recommended investors buy Coherus a few weeks ago under the IPO price when it was trading around $13.10.

Roth Capital Reiterates Buy On Concert Following Initiation Of Phase I Study

In a research report issued yesterday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Concert Pharmaceuticals (NASDAQ:CNCE) with a $28 price target, …

Roth Capital Highlights Key Points From Concert’s Partner Avanir Positive Phase II Results Of AVP-923

In a research report issued yesterday, Roth Capital analyst Joseph Pantginis maintained a Buy rating on Concert Pharmaceuticals (NASDAQ:CNCE) with a $28 price …

Roth Capital Reiterates Buy On Concert Pharma Shares, $28 PT

In a research report issued yesterday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Concert Pharmaceuticals (NASDAQ:CNCE) with a price target of …

Concert Pharmaceuticals Bullish Stance Reiterated At Roth Capital Following Positive Meeting With FDA

In a research note released yesterday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Concert Pharmaceuticals Inc. (CNCE) with a $28.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts